Is pharmacogenomics a reality? Challenges and oppurtunities for India
2011
Challenges and Opportunities in Pharmacogenomics for India
Editorial
Evidence: moderate
Author Information
Author(s): Moinak Banerjee
Primary Institution: Rajiv Gandhi Center for Biotechnology
Hypothesis
How can pharmacogenomics improve drug response and safety in the Indian population?
Conclusion
Pharmacogenomic profiling has the potential to significantly enhance drug response monitoring and reduce economic burdens in India.
Supporting Evidence
- 40% of medicines taken daily are not effective, leading to significant economic waste.
- Pharmacogenomic profiling can minimize the economic burden of drug response.
- India's pharmaceutical market primarily consists of generic drugs, limiting access to newer medications.
- Genomic technologies have drastically reduced the cost of genome sequencing.
- More than 90% of Americans prefer pharmacogenomic profiling for drug dosing and selection.
Takeaway
Pharmacogenomics is like a special tool that helps doctors choose the right medicine for each person based on their genes, which can make medicines work better and safer.
Limitations
India is currently behind in pharmacogenomic technologies and drug response monitoring.
Participant Demographics
The Indian population is diverse, stratified by religion, caste, and linguistic affiliations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website